Prenetics, a NASDAQ-listed company, has agreed to sell its stake in ACT Genomics Holdings to Delta Electronics for $71.78 million. This strategic divestiture bolsters Prenetics' financial position, increasing its cash reserves to approximately $86 million and total cash and short-term assets to $117 million. With a debt-free balance sheet, Prenetics is now positioned to explore digital asset adoption and Bitcoin financial strategies.